Covid-19 Predictors: Safety of Gynecological Oncology Patients Undergoing Systemic Cancer Therapy
NCT ID: NCT05043220
Last Updated: 2024-11-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
NA
100 participants
INTERVENTIONAL
2021-09-29
2025-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Early Detection of Cancers in Low Resource Countries
NCT01178736
Role of Mitochondrial Bioenergetics in Resilience for Gynecologic Cancer
NCT07046936
Side Effects Screening and Early Intervention to Impact in Quality of Life of Gynaecological Cancer Patients
NCT05918770
Patient Related Outcomes for Gynecologic Radiation Oncology
NCT04753086
Impact of the COVID-19 Pandemic in Gynecological Oncology
NCT04351139
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
SUPPORTIVE_CARE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Telemedicine
Telemonitoring via PPG (photoplethysmography) and PROM (patient reported outcome monitoring) via app
PPG and PROM
description will follow
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PPG and PROM
description will follow
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* indication for systemic cancer therapy
* patients who are legally competent and able to understand and follow instructions of the study staff
* present informed consent
Exclusion Criteria
* persons who are in a dependency or employment relationship with the study center
* positive proof of COVID-19
* affection of the external auditory canal
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Technical University of Munich
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Heike Jansen
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Heike Jansen, Dr. med
Role: PRINCIPAL_INVESTIGATOR
Technical University of Munich
Marion Kiechle, Prof. Dr. med.
Role: STUDY_DIRECTOR
Technical University of Munich
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Klinikum rechts der Isar, Frauenklinik, Technische Universität München
Munich, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CO-SI-ONKO
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.